<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978767</url>
  </required_header>
  <id_info>
    <org_study_id>201901202</org_study_id>
    <nct_id>NCT03978767</nct_id>
  </id_info>
  <brief_title>Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial</brief_title>
  <acronym>PANDA</acronym>
  <official_title>Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized non-inferiority trial of women with preeclampsia with severe features to
      determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior
      to standard analgesic bundles in their impact on postpartum hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently published clinical guidelines for the care of women with hypertensive disorders
      recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) should be withheld from
      patients with hypertension that persists for more than one day postpartum (1). This
      recommendation is based in data from the general medicine literature, which suggests a role
      of NSAIDs in precipitating hypertension in non-pregnant adults (2,3). It may also draw from
      previously published case reports of post-partum hypertension that were thought to be NSAID
      induced (4). There has been a paucity of data from the obstetric literature to support or
      rebuff this recommendation. As the opioid crisis worsens in the United States, additional
      attention and resources have focused on limiting the use of narcotic medications. The
      effective employment of non-opioid analgesics has been shown to reduce narcotic use (5).
      Ibuprofen and other NSAIDs are the most effective and most commonly prescribed analgesics for
      postpartum pain, but clinicians now find themselves stuck between these recommendations and
      their efforts to limit unnecessary opioid prescriptions.

      The investigators propose a randomized controlled non-inferiority trial of women with
      preeclampsia comparing a postpartum analgesic protocol that includes NSAIDs, to one that
      excludes them. The central hypothesis is that NSAID use does not worsen hypertensive diseases
      of pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">July 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized non-inferiority clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postpartum antihypertensive requirements</measure>
    <time_frame>at the end of hospitalization, up to 7 days after randomization</time_frame>
    <description>measurement of anti-hypertensive requirements at time of discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postpartum pain scores</measure>
    <time_frame>From randomization to 6 weeks after randomization</time_frame>
    <description>Evaluate the effect of NSAIDs on patient perception of pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum opioid use</measure>
    <time_frame>From randomization to 6 weeks after randomization</time_frame>
    <description>Compare the opioid requirements in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>From randomization to 6 weeks after randomization</time_frame>
    <description>Compare peak, average and median MAPs postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End organ damage</measure>
    <time_frame>during hospitalization, an average of 4 days</time_frame>
    <description>Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission</measure>
    <time_frame>From randomization to 6 weeks after randomization</time_frame>
    <description>Evaluate the incidence of hospital readmission rate postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continued anti-hypertensive requirement</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>evaluate the need for antihypertensive medications at 6 weeks postpartum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Preeclampsia Severe</condition>
  <condition>Preeclampsia Postpartum</condition>
  <arm_group>
    <arm_group_label>NSAID Analgesic bundle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID free analgesic bundle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg</intervention_name>
    <description>NSAID pain medication to be used in the experimental bundle for postpartum analgesia</description>
    <arm_group_label>NSAID Analgesic bundle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section</description>
    <arm_group_label>NSAID Analgesic bundle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Analgesic medication to be used in both treatment arms</description>
    <arm_group_label>NSAID Analgesic bundle</arm_group_label>
    <arm_group_label>NSAID free analgesic bundle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Analgesic medication to be used in both treatment arms</description>
    <arm_group_label>NSAID Analgesic bundle</arm_group_label>
    <arm_group_label>NSAID free analgesic bundle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women at &gt; 23 weeks gestational age undergoing vaginal or cesarean delivery at
             Barnes-Jewish Hospital with:

          -  An antepartum diagnosis of preeclampsia with severe features

          -  Pre-eclampsia with severe features will be defined as:

          -  Elevated blood pressure ≥ 160/110, or

          -  Pre-eclampsia in the setting of thrombocytopenia (platelet count &lt; 100,000), or

          -  Impaired liver function (AST elevated to twice upper limit of normal), or

          -  Persistent epigastric pain, or

          -  Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or

          -  Pulmonary edema, or

          -  New onset visual disturbance or headache unresponsive to therapy.

        Exclusion Criteria:

          -  NSAID allergy

          -  Allergy to acetaminophen

          -  Antihypertensive use in this pregnancy prior to 20 weeks gestation

          -  Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60
             mL/min

          -  Inability to obtain consent

          -  Opioid abuse disorder

          -  Peptic ulcer disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan S Hirshberg, MD</last_name>
    <phone>314-362-5000</phone>
    <email>jhirshberg@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Burger</last_name>
    <phone>3147471390</phone>
    <email>tburger@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hirshberg, MD</last_name>
      <phone>314-362-5000</phone>
      <email>jhirshberg@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88.</citation>
    <PMID>24150027</PMID>
  </reference>
  <reference>
    <citation>Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013 Apr;25(2):124-32. doi: 10.1097/GCO.0b013e32835e0ef5. Review.</citation>
    <PMID>23403779</PMID>
  </reference>
  <reference>
    <citation>Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005 Feb 26-Mar 4;365(9461):785-99. Review.</citation>
    <PMID>15733721</PMID>
  </reference>
  <reference>
    <citation>Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HH. Hypertensive disorders of pregnancy and postpartum readmission in the United States: national surveillance of the revolving door. J Hypertens. 2018 Mar;36(3):608-618. doi: 10.1097/HJH.0000000000001594.</citation>
    <PMID>29045342</PMID>
  </reference>
  <reference>
    <citation>Viteri OA, England JA, Alrais MA, Lash KA, Villegas MI, Ashimi Balogun OA, Chauhan SP, Sibai BM. Association of Nonsteroidal Antiinflammatory Drugs and Postpartum Hypertension in Women With Preeclampsia With Severe Features. Obstet Gynecol. 2017 Oct;130(4):830-835. doi: 10.1097/AOG.0000000000002247.</citation>
    <PMID>28885417</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jonathan (Jake) Hirshberg</investigator_full_name>
    <investigator_title>Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>NSAIDs</keyword>
  <keyword>Ibuprofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03978767/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

